Barclays
ADIL

Barclays’s Adial Pharmaceuticals ADIL Stock Holding History

Barclays’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25
Closed -$38K – 4854
2021
Q1 		$38K Buy
+25
New +$37.8K ﹤0.01% 4255
2019
Q4 		– Hold
0
– – – 6304
2019
Q3 		– Hold
0
– – – 6663
2019
Q2 		– Hold
0
– – – 6899
2019
Q1 		– Hold
0
– – – 6971

Other funds holding ADIL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Barclays's ADIL Position: Q2 2021 in Review

Barclays sold out of Adial Pharmaceuticals (ADIL) in Q2 2021, closing a stake of 25 shares — an estimated $38K sold.

Barclays first reported a position in ADIL in Q1 2021 and held it in 1 quarter. The position peaked at $38K in Q1 2021. 18 funds tracked by Wall St. Rank hold ADIL as of Q2 2021.

  • Barclays reported no remaining Adial Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Barclays sold 25 Adial Pharmaceuticals shares in Q2 2021, an estimated $38K.
  • Barclays first reported a position in Adial Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Barclays's Adial Pharmaceuticals position peaked at $38K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.